Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster dose of inactivated Vero-cell-derived Japanese encephalitis vaccine (JEVAC) in children primed with live attenuated JE vaccine
TCTR20190507007Phase 4Not yet recruiting
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of japanese encephalitis vaccine (vero cell), inactivated in Japanese encephalitis (JE), sponsored by Liaoning Chengda Biotechnology Co., Ltd.. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
japanese encephalitis vaccine (vero cell), inactivated
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on TCTR20190507007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190507007.